Similar to cytoplasmic Kaiso, LC3A/B is (1) preferentially expressed in more aggressive forms of breast cancer including LumB, HER2, and TNBC (Fig. 3e); and (2) preferentially elevated in ER- compared to ER+ tumors with a trend toward higher expression in women of African compared to European ancestry (Fig. 3f). This evidence concerns the gene MAP1LC3A and breast carcinoma.